Clinical trial · Observational
Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
"Epidemiology, Approaches to the Diagnosis and Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In connection with the transition to the 8th version of the classification of lung cancer according to the TNM system, there are currently no precise epidemiological data on stage III NSCLC, clinical characteristics of patients in this group, approaches to therapy and treatment results in the Russian Federation. The published statistics only provide information on the overall incidence of stage III lung, trachea and bronchial cancer, which is about 40%. This observational study will make it possible to characterize the Russian population of stage III non-small cell lung cancer patients, approaches to choosing a treatment option for stage III NSCLC and the outcomes of this treatment in real clinical practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage III Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Examine clinical and morphological groups
- timeFrame
- 10/01/2023
- description
- * gender ratio (husband, wife) * smoking status (smoker, non-smoker, past smoker) * proportional distribution: squamous cell, adenocarcinoma, dimorphic cancer, others) * how many patients with mediastinal lymph node involvement: (N0, N1, N2, N3) * detection frequency: PDL (PDL \<1, PDL\> 1, PDL \<49, PDL\> 50), EGFR (EGFR + (19.24 exon) EGFR-), (ALK +, ALK -), (ROS-1 +, ROS-1 -) Get information about regional algorithms * Variants of treatment tactics: Percentage: a. Surgery v. Chemotherapy -Diagnostic algorithm: a. Morphological verification frequency b. The frequency of confirmation of metastatic lesions within the thoracic lymph nodes c. F
Secondary outcomes (3)
- measure
- Explore clinical approaches
- timeFrame
- 10/01/2023
- description
- * Percentage of treatment options depending on: a. histological type * squamous * adenocarcinoma * dimorphic * 3 A st * 3B st
- measure
- Diagnostic algorithm:
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: \- stage III non-small cell lung cancer Exclusion Criteria: \- the rest of the disease stage
References
Publications (0)
Data not yet available